Ab­b­Vie hus­tles its uni­corn drug Ro­va-T in­to the clin­ic in com­bo with Bris­tol's Op­di­vo

Ab­b­Vie is wast­ing lit­tle time in get­ting its new­ly ac­quired drug Ro­va-T in­to the clin­ic for small cell lung can­cer in com­bi­na­tion with a check­point …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.